Overview

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

Status:
Completed

Trial end date:
2018-04-03

Target enrollment:

Participant gender:

Summary

This is a multicentre study examining the use of Advagraf-minimization strategy and/or the use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal allografts.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Astellas Pharma Canada, Inc.

Treatments:

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Basiliximab
Enzyme Inhibitors
Irbesartan
Methylprednisolone
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Ramipril
Tacrolimus